Skip to main content
SpringerLink
Log in

Novel Molecules

  • Chapter
  • First Online:
Chronic Kidney Disease and Hypertension

Part of the book series: Clinical Hypertension and Vascular Diseases ((CHVD))

  • 2305 Accesses

Abstract

Novel approaches and drugs to improve hypertension treatment are permanently under investigation. Human recombinant renalase is being tested in animal models and new options to block the renin–angiotensin–aldosterone axis such as renin inhibitors, angiotensin II type 2 receptor agonists, angiotensin vaccines and aldosterone synthase inhibitors are under scrutiny with variable results so far. Interventions in different hormones and autacoids, enzymatic and cellular signalling pathways like vasopeptidase inhibitors, activators and stimulators of soluble guanylyl cyclase, soluble epoxide hydrolase inhibitors and endothelin receptor antagonists, among others, are all work in progress. Objectives with newer agents are to optimize blood pressure control and minimize end-organ damage beyond what has been achieved so far. Adverse effects will limit some of these new therapeutic approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

C21:

Compound 21

cGMP:

Cyclic guanosine 3′,5′-monophosphate

COX:

Cyclooxygenase

CYP:

Cytochrome P-450

ET-1:

Endothelin 1

ET-2:

Endothelin 2

ET-3:

Endothelin 3

ETA:

Endothelin receptor type A

ETB:

Endothelin receptor type B

ETEs:

Epoxyeicosatrienoic acids

ETRA:

Endothelin receptor antagonist

FDA:

Food and Drug Administration

HETEs:

Hydroxyeicosatetraenoic acids

KO:

Knockout

LOX:

Lipoxygenase

LTs:

Leucotrienes

LXs:

Lipoxins

MR:

Mineralocorticoid receptors

NEP:

Neutral endopeptidase

NO:

Nitric oxide

sEH:

Soluble epoxide hydrolase

sGC:

Soluble guanylyl cyclase

References

  1. Paulis L, Unger T. Novel therapeutic targets for hypertension. Nat Rev Cardiol. 2010;7(8):431–41.

    Article  CAS  PubMed  Google Scholar 

  2. Xu J, Wang P, Velazquez H, Yao X, Li Y, Wu Y, et al. Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Ivest. 2005;115:1275–80.

    Article  CAS  Google Scholar 

  3. Desir GV, Tang L, Wang P, Li G, Sampaio Maia B, Quelhas-Santos J, et al. Renalase lowers ambulatory blood pressure by metabolizing circulating catecholamines. J Am Heart Assoc. 2012;1:e002634.

    Article  PubMed Central  PubMed  Google Scholar 

  4. Wu Y, Xu J, Velazquez H, Wang P, Li G, Liu D, Sampaio-Maia B, Quelhas-Santos J, et al. Renalase deficiency aggravates ischemic myocardial damage. Kidney Int. 2011;79(8):853–60.

    Article  CAS  PubMed  Google Scholar 

  5. Jiang W, Guo Y, Tan L, Tang X, Yang Q, Yang K. Impact of renal denervation on renalase expression in adult rats with spontaneous hypertension. Exp Ther Med. 2012;4(3):493–6.

    PubMed Central  CAS  PubMed  Google Scholar 

  6. Baraka A, El Ghotny S. Cardioprotective effect of renalase in 5/6 nephrectomized rats. J Cardiovasc Pharmacol Ther. 2012;17(4):412–6.

    Article  CAS  PubMed  Google Scholar 

  7. Desir GV, Wang L, Peixoto AJ. Human renalase: a review of its biology, function, and implications for hypertension. J Am Soc Hypertens. 2012;6(6):417–26.

    Article  CAS  PubMed  Google Scholar 

  8. Tissot AC, Maurer P, Nussberger J, Sabat R, Pfister T, Ignatenko S, et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet. 2008;371:821–7.

    Article  CAS  PubMed  Google Scholar 

  9. Nakagami F, Koriyama H, Nakagami H, Osako MK, Shimamura M, Kyutoku M, et al. Decrease in blood pressure and regression of cardiovascular complications by angiotensin II vaccine in mice. PLoS ONE. 2013;8(3):e60493.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Chen X, Qiu Z, Yang S, Ding D, Chen F, Zhou Y, et al. Effectiveness and safety of a therapeutic vaccine against angiotensin II receptor yype 1 in hypertensive animals. Hypertension. 2013;61:408–16.

    Article  CAS  PubMed  Google Scholar 

  11. Foulquier S, Steckelingd UM, Unger T. Impact of the AT2 receptor agonist C21 on blood pressure and beyond. Curr Hypertens Rep. 2012;14:403–9.

    Article  CAS  PubMed  Google Scholar 

  12. Steckelings UM, Kaschina E, Unger T. The AT2 receptor-a matter of love and hate. Peptides. 2005;26:1401–9.

    Article  CAS  PubMed  Google Scholar 

  13. Rehman A, Leibowitz A, Yamamoto N, Rautureau Y, Paradise P, Schiffrin EL. Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension. 2012;59:291–9.

    Article  CAS  PubMed  Google Scholar 

  14. Hilliard LM, Jones ES, Steckelings UM, Unger T, Widdop RE, Denton KM. Sex-specific influence of angiotensin type 2 receptor stimulation on renal function: a novel therapeutic target for hypertension. Hypertension. 2012;59:409–14.

    Article  CAS  PubMed  Google Scholar 

  15. Trunet PF, Mueller P, Girard F, Aupetit B, Bhatnagar AS, Zognbi F, et al. Effects of fadrozole hydrochloride on aldosterone secretion in healthy male subjects. J Clin Endocrinol Metab. 1992;74:571–6.

    CAS  PubMed  Google Scholar 

  16. Fiebeler A, Nussberger J, Shagdarsuren E, Rong S, Hilfenhaus G, Al-Saadi N, et al. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation. 2005;111:3087–94.

    Article  CAS  PubMed  Google Scholar 

  17. Calhoun DA, White WB, Krum H, Guo W, Bermann G, Trapani A, et al. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomised, double-blind, placebo- and active-controlled phase 2 trial. Circulation. 2011;124:1945–55.

    Article  CAS  PubMed  Google Scholar 

  18. Amar L, Azizi M, Menard J, Peyrard S, Watson C, Plouin PF. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension. 2010;56:831–8.

    Article  CAS  PubMed  Google Scholar 

  19. Azizi M, Amar L, Menard J. Aldosterone synthase inhibitions in humans. Nephrol Dial Transplant. 2013;28:36–43.

    Article  CAS  PubMed  Google Scholar 

  20. Campbell JC. Vasopeptidase inhibition: a double-edged sword? Hypertension. 2003;41:383–9.

    Article  CAS  PubMed  Google Scholar 

  21. Ruilope LM, Dukat A, Bohm M, Lacourciere Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375:1255–66.

    Article  CAS  PubMed  Google Scholar 

  22. Unger T, Paulis L, Sica DA. Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches. Eur Heart J. 2011;32: 2739–47.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the omapatrilat cardiovascular treatment vs. enalapril (OCTAVE) trial. Am J Hypertens. 2004;17:103–111.

    Article  CAS  PubMed  Google Scholar 

  24. Nossaman B, Pankey E, Kadowitz P. Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications. Crit Care Res Pract. 2012;2012:290805.

    PubMed Central  PubMed  Google Scholar 

  25. Grimminger F, Weimann G, Frey R, Voswinckel R, Thamm M, Bölkow D, et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J. 2009;33(4):785–92.

    Article  CAS  PubMed  Google Scholar 

  26. Imig JD. Epoxides and soluble epoxi hydrolase in cardiovascular physiology. Physiol Rev. 2011;92:101–30.

    Article  Google Scholar 

  27. Shen HC, Hammock BD. Discovery of inhibitors of soluble epoxi hydrolase: a target with multiple potential therapeutic indications. J Med Chem. 2012;55(5):1789–808.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Imig JD, Hammock BD. Soluble epoxi hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov. 2009;8(10):794–805.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Rautureau Y, Schiffrin EL. Endothelin in hypertension: an update. Curr Opin Nephrol Hypertens. 2012;21(2):128–36.

    Article  CAS  PubMed  Google Scholar 

  30. Barton M, Yanagisawa M. Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol. 2008;86(8):485–98.

    Article  CAS  PubMed  Google Scholar 

  31. Weber MA, Black H, Bakris G, Krum H, Linas S, Weiss R, et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:1423–31.

    Article  CAS  PubMed  Google Scholar 

  32. Bakris GL, Lindholm LH, Black H, Krum H, Linas S, Linseman JV, et al. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension. 2010;56:824–30.

    Article  CAS  PubMed  Google Scholar 

  33. Dhaun N, MacIntyre IM, Kerr D, Melville V, Johnston NR, Haughie S, et al. Selective endothelin-a receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension. 2011;57:772–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology, Sanatorio Allende Cordoba, Av. O’Higgins 5390, 5014, Cordoba, Cordoba, Argentina

    Valeria Lourdes Vukelic & Marcelo Orias

Authors
  1. Valeria Lourdes Vukelic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marcelo Orias
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Valeria Lourdes Vukelic .

Editor information

Editors and Affiliations

  1. Division of Nephrology, University of Maryland School of Medicine, Baltimore, Maryland, USA

    Matthew R. Weir

  2. Section of Nephrology, University of Illinois at Chicago/Advocate Christ Medical Center, Oak Lawn, Illinois, USA

    Edgar V. Lerma

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Vukelic, V., Orias, M. (2015). Novel Molecules. In: Weir, M., Lerma, E. (eds) Chronic Kidney Disease and Hypertension. Clinical Hypertension and Vascular Diseases. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-1982-6_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-1982-6_5

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-1981-9

  • Online ISBN: 978-1-4939-1982-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation